Estrogen, Lipid Oxidation, and Body Fat
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
To the Editor: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, widely prescribed to treat hypercholesterolemia, are clearly effective and are associated with reductions in mortality from coronary disease and overall mortality.1 Toxic effects on skeletal muscle, which may range from diffuse myalgia to severe rhabdomyolysis, are a known side effect of these drugs. 2 Interactions of HMG-CoA reductase inhibitors with cyclosporine, and less often with gemfibrozil and niacin, increase the risk of rhabdomyolysis.2 We report a case of severe rhabdomyolysis from the coadministration of lovastatin, niacin, and itraconazole.A 63-year-old woman with familial hypercholesterolemia and a previous myocardial infarction who had undergone coronary-artery bypass surgery at the age of 50, was treated with 80 mg of lovastatin and 3 g of niacin daily, plus timolol maleate and aspirin, for almost 10 years without evidence of toxic effects.In March 1995, scaling lesions developed on her abdomen.A dermatologist diagnosed tinea corporis and prescribed 100 mg of itraconazole (Sporanox) twice daily.The patient was advised to continue her regular medications.Two weeks later weakness developed in her arms, back, and legs, along with pain on motion and tenderness to touch.After 2 1 ⁄ 2 weeks, when her urine turned dark, then frankly brown, the patient sought medical attention.On examination, her muscles were tender and very weak.Her urine was brown, cloudy, and strongly positive for heme.Treatment with itraconazole, lovastatin, and niacin was stopped immediately, and treatment with 210 mg of oral ubiquinone (coenzyme Q) daily was begun.Ubiquinone has been reported to ameliorate the toxic effects of lovastatin.3 Blood counts and renal-function tests were normal.The serum concentration of aldolase (specific for skeletal muscle) was 75 U per liter (10 times the normal value).Initial values for serum creatine kinase, aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase were 32,700, 1145, 382, and 1225 U per liter, respectively, and over the next four days these values peaked at 47,100, 1390, 581, and 2217 U per liter.A diagnosis of drug-induced rhabdomyolysis and hepatotoxicity was made.Over the next 18 days, the elevated serum enzyme values gradually returned to normal, and the symptoms disappeared; ubiquinone was then stopped.The patient's plasma cholesterol level, which was 253 mg per deciliter while she was taking lovastatin but before the itraconazole therapy, was 193 mg per deciliter while she was taking both lovastatin and itraconazole, and it gradually rose to 465 mg per deciliter after both drugs were discontinued.Niacin therapy (3 g daily) was started again 11 weeks later, without evidence of toxicity.This patient had severe rhabdomyolysis when itraconazole was added to a stable regimen that included lovastatin as well as niacin.Both the cholesterol-lowering statins (lovastatin, pravastatin, simvastatin, and fluvastatin) and the antifungal azoles (itraconazole, ketoconazole, clotrimazole, and miconazole) inhibit sterol synthesis.4 However, the cause of our patient's toxic reaction is not clear, and it is also not clear whether ubiquinone modified the course of that reaction.Since cholesterol-lowering therapy can safely be suspended for short periods, it seems prudent either to discontinue treatment with statins temporarily while using itraconazole and similar drugs or to use alternative antifungal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Cited by
Estrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542
Self-citationMauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1146 · Cited by 341
O'Sullivan, A. J., Crampton, L. J., Freund, J., & Ho, K. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2773 · Cited by 210
“Along with our earlier observations that a different oral estrogen formulation suppressed lipid oxidation (27) and IGF-I levels (1), the reduction in lipid oxidation detected in the present study is also likely to be a first pass hepatic effect of orally administered estrogen.”
BackgroundResultSelf-citationOral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women
Wolthers, T., Hoffman, D. M., Nugent, A. G., Duncan, M. W., Umpleby, M., & Ho, K. K. Y. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1191 · Cited by 114
Self-citationGormsen, L. C., Høst, C., Hjerrild, B. E., Pedersen, S. B., Nielsen, S., Christiansen, J. S., & Gravholt, C. H. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0422 · Cited by 42
Metadata
- Authors
- O'Sullivan, A. J., Hoffman, D. M., & Ho, K. K. Y.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-09-07
- Volume
- 333
- Issue
- 10
- Pages
- 669-670
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1967277821
- Cited by
- 39
- References
- 1
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogen, Lipid Oxidation, and Body Fat. https://app.cochat.ai/papers/10.1056/nejm199509073331018
- The paper
- O'Sullivan, A. J., Hoffman, D. M., & Ho, K. K. Y. (1995). Estrogen, Lipid Oxidation, and Body Fat. New England Journal of Medicine. https://doi.org/10.1056/nejm199509073331018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.